Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.

Lu Y, Cheng Z, Zhao Y, Chang X, Chan C, Bai Y, Cheng N.

Atherosclerosis. 2016 Nov;254:215-227. doi: 10.1016/j.atherosclerosis.2016.10.025. Epub 2016 Oct 14.

PMID:
27764723
2.

Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.

ChruĊ›ciel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, Jones SR, Mosteoru S, Blaha MJ, Martin SS, Rysz J, Toth PP, Lip GY, Pencina MJ, Ray KK, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group..

Atherosclerosis. 2016 Oct;253:194-208. doi: 10.1016/j.atherosclerosis.2016.07.897. Epub 2016 Jul 15.

PMID:
27498397
3.

Statin use and the risk of developing diabetes: a network meta-analysis.

Thakker D, Nair S, Pagada A, Jamdade V, Malik A.

Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1131-1149. doi: 10.1002/pds.4020. Epub 2016 Jun 9.

PMID:
27277934
4.

Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.

Gosho M, Tanahashi M, Hounslow N, Teramoto T.

Int J Clin Pharmacol Ther. 2015 Aug;53(8):635-46. doi: 10.5414/CP202195.

PMID:
26104032
5.

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.

Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, Michishita I, Nozue T, Sugiyama S, Tsimikas S, Yoshida H, Ray KK.

Atherosclerosis. 2015 Aug;241(2):409-18. doi: 10.1016/j.atherosclerosis.2015.06.001. Epub 2015 Jun 4.

PMID:
26074315
6.

A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients.

Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM.

Am J Cardiol. 2015 Jun 15;115(12):1760-6. doi: 10.1016/j.amjcard.2015.03.025. Epub 2015 Mar 24. Review.

PMID:
25907504
7.

Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials.

Ma N, Cui L.

Drug Des Devel Ther. 2015 Mar 31;9:1859-64. doi: 10.2147/DDDT.S67448. eCollection 2015 Mar 31.

8.

Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants.

Talameh JA, Kitzmiller JP.

J Pharmacogenomics Pharmacoproteomics. 2014 Apr 23;5(2). pii: 128.

9.

Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials.

Jiang Z, Gong RR, Qiu L, Wang Q, Su M, Liu XJ, Hu MS, Lin J, Fang DZ.

Clin Drug Investig. 2014 Sep;34(9):599-608. doi: 10.1007/s40261-014-0215-0. Review.

PMID:
25022719
10.

Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.

Liu G, Zheng XX, Xu YL, Lu J, Hui RT, Huang XH.

Heart Lung Circ. 2014 Oct;23(10):970-7. doi: 10.1016/j.hlc.2014.05.005. Epub 2014 May 28. Review.

PMID:
24954758
11.

Prophylaxis of thromboembolic events in patients with nephrotic syndrome.

Pincus KJ, Hynicka LM.

Ann Pharmacother. 2013 May;47(5):725-34. doi: 10.1345/aph.1R530. Epub 2013 Apr 23. Review.

PMID:
23613095
12.

Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.

Keating AJ, Campbell KB, Guyton JR.

Ann Pharmacother. 2013 Mar;47(3):398-404. doi: 10.1345/aph.1R509. Epub 2013 Mar 12. Review.

PMID:
23482733
13.

Teratogenic risk of statins in pregnancy.

Godfrey LM, Erramouspe J, Cleveland KW.

Ann Pharmacother. 2012 Oct;46(10):1419-24. doi: 10.1345/aph.1R202. Epub 2012 Oct 2. Review.

PMID:
23032657
14.

Pleiotropic effects of pitavastatin.

Davignon J.

Br J Clin Pharmacol. 2012 Apr;73(4):518-35. doi: 10.1111/j.1365-2125.2011.04139.x. Review.

15.

Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.

Alberton M, Wu P, Druyts E, Briel M, Mills EJ.

QJM. 2012 Feb;105(2):145-57. doi: 10.1093/qjmed/hcr158. Epub 2011 Sep 14.

PMID:
21920996
16.

Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.

Yee LL, Wright EA.

Clin Ther. 2011 Aug;33(8):1023-42. doi: 10.1016/j.clinthera.2011.07.011. Epub 2011 Aug 4. Review.

PMID:
21816477
17.

Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.

Poolsup N, Suksomboon N, Wongyaowarat K, Rungkanchananon B, Niyomrat P, Kongsuwan S.

J Clin Pharm Ther. 2012 Apr;37(2):166-72. doi: 10.1111/j.1365-2710.2011.01274.x. Epub 2011 May 18. Review.

PMID:
21585411
18.

Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?

Ikewaki K, Ayaori M.

Circ J. 2011;75(6):1326-7. Epub 2011 Apr 29. No abstract available.

19.

Pitavastatin: a new HMG-CoA reductase inhibitor.

Wensel TM, Waldrop BA, Wensel B.

Ann Pharmacother. 2010 Mar;44(3):507-14. doi: 10.1345/aph.1M624. Epub 2010 Feb 23. Review.

PMID:
20179258
20.

Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.

Saito Y.

Vasc Health Risk Manag. 2009;5:921-36. Epub 2009 Nov 16. Review.

Supplemental Content

Loading ...
Support Center